Bespoke assays to screen compounds against exciting new UPS targets as they continue to emerge across a wide range of human diseases
Our extensive expertise in the Ubiquitin Proteosome System (UPS) combined with access to our high-quality reagents allows Ubiquigent’s Custom Assay Development team to support biotech and pharma in translating new discoveries in this rapidly emerging space into drug discovery programmes.
Ubiquigent has successfully developed and delivered many high-throughput assays for screening projects against UPS targets of high therapeutic value, such as DUBs and E3 ligases.